SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution.

AnnaMaria Maraschi, Valentina Gumina, Jessica Dragotto, Claudia Colombrita, Miguel Mompeán, Emanuele Buratti, Vincenzo Silani, Marco Feligioni, Antonia Ratti

Journal: Molecular neurobiology 2022;58(11):5682-5702

PMID: 34390468

Abstract

The nuclear RNA-binding protein TDP-43 forms abnormal cytoplasmic aggregates in the brains of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients and several molecular mechanisms promoting TDP-43 cytoplasmic mislocalization and aggregation have been proposed, including defects in nucleocytoplasmic transport, stress granules (SG) disassembly and post-translational modifications (PTM). SUMOylation is a PTM which regulates a variety of cellular processes and, similarly to ubiquitination, targets lysine residues. To investigate the possible regulatory effects of SUMOylation on TDP-43 activity and trafficking, we first assessed that TDP-43 is SUMO-conjugated in the nuclear compartment both covalently and non-covalently in the RRM1 domain at the predicted lysine 136 and SUMO-interacting motif (SIM, 106-110 residues), respectively. By using the SUMO-mutant TDP-43 K136R protein, we demonstrated that SUMOylation modifies TDP-43 splicing activity, specifically exon skipping, and influences its sub-cellular localization and recruitment to SG after oxidative stress. When promoting deSUMOylation by SENP1 enzyme over-expression or by treatment with the cell-permeable SENP1 peptide TS-1, the cytoplasmic localization of TDP-43 increased, depending on its SUMOylation. Moreover, deSUMOylation by TS-1 peptide favoured the formation of small cytoplasmic aggregates of the C-terminal TDP-43 fragment p35, still containing the SUMO lysine target 136, but had no effect on the already formed p25 aggregates. Our data suggest that TDP-43 can be post-translationally modified by SUMOylation which may regulate its splicing function and trafficking, indicating a novel and druggable mechanism to explore as its dysregulation may lead to TDP-43 pathological aggregation in ALS and FTD.

© 2021. The Author(s).

Address: Department of Neurology, Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Piazzale Brescia 20, 20149, Milan, Italy.; Laboratory of Neuronal Cell Signaling, EBRI Rita Levi-Montalcini Foundation, Viale Regina Elena 295, 00161, Rome, Italy.; "Rocasolano" Institute for Physical Chemistry, Spanish National Research Council, Serrano 119, 28006, Madrid, Spain.; International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano 99, 34149, Trieste, Italy.; Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Università Degli Studi Di Milano, Via A. di Rudinì 8, 20142, Milan, Italy.; Department of Pathophysiology and Transplantation, Dino Ferrari" Center, Università Degli Studi Di Milano, Via F. Sforza 35, 20122, Milan, Italy.; Department of Neurorehabilitation Sciences, Casa Di Cura del Policlinico, Via Giuseppe Dezza 48, 20144, Milan, Italy.; Department of Neurology, Stroke Unit and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Piazzale Brescia 20, 20149, Milan, Italy. [email protected].; Department of Medical Biotechnology and Translational Medicine, Università Degli Studi Di Milano, Via Fratelli Cervi 93, 20090, Segrate, Milan, Italy. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.